Purple Biotech ( (PPBT) ) has provided an update.
On April 16, 2025, Purple Biotech announced the publication of a study in the Neuro Oncology Journal highlighting the potential of their drug NT219 to suppress brain metastasis in colorectal cancer. The study, conducted in collaboration with Tel Aviv University and Sourasky Medical Center, showed that NT219, in combination with 5-fluorouracil, inhibits colorectal cancer brain metastasis through the IRS2 pathway. This research identifies IRS2 as a driver of brain metastasis and suggests that NT219 could significantly impact treatment strategies for colorectal cancer patients, potentially prolonging their survival.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.
Purple Biotech’s overall stock score reflects significant financial distress, with zero revenue, persistent net losses, and negative cash flow. The technical analysis suggests a bearish trend, and valuation metrics are poor due to a negative P/E ratio and absence of dividend yield. The company needs strategic changes to address operational inefficiencies and improve revenue generation.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance. Their oncology pipeline includes products like CM24, NT219, and CAPTN-3, which target various cancer mechanisms and pathways. The company is headquartered in Rehovot, Israel.
YTD Price Performance: -45.53%
Average Trading Volume: 20,772
Technical Sentiment Signal: Buy
Current Market Cap: $7.04M
For a thorough assessment of PPBT stock, go to TipRanks’ Stock Analysis page.